Health Care Innovation

Chaos has become the norm at the U.S. Food and Drug Administration. And it’s putting American patients, not to mention our country’s world-leading life sciences sector, at risk. Earlier this year, roughly 3,500 FDA employees were laid off. The agency’s Center for Drug Evaluation and Research, which oversees prescription and ...

In November, a group of Democrats in the U.S. House made clear that they’ll sacrifice medical innovation for lower drug prices if they ever reclaim Congress. Patients today and tomorrow will be the losers in that trade. Read the op-ed here.

Joining the Senate, the U.S. House of Representatives is now taking up the problem of skyrocketing healthcare costs. Democrats have proposed extending the expanded subsidies for the Affordable Care Act (aka, Obamacare or ACA), but this will not address the problem of rising costs. Promoting greater healthcare affordability requires reforms ...

A new federal audit reveals that five states have spent a total of more than $1 billion providing Medicaid benefits to illegal immigrants. According to Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services (CMS), “If you live in Texas or Florida, and you’re paying U.S. federal ...

In rural America, quality medical care can be hard to come by. The Rural Health Transformation Program that’s part of the budget reconciliation package that became law this summer aims to change that. The $50 billion program seeks to improve healthcare access, quality, and outcomes in rural America. All worthy ...

Congress has handed hospital giants a new line of taxpayer-funded credit. This summer, Congress included a $50 billion “rural health fund” in the multitrillion-dollar One Big Beautiful Bill Act. The fund’s supporters are touting it as a lifeline for struggling community hospitals. But small-town emergency rooms will not be the ...

The new class of GLP-1 medicines exemplifies both the potential of pharmaceutical innovation and the risks to future advancements from ill-considered government policies. The incredible benefits from GLP-1’s are clear – they significantly improve our health and well-being. Risks arise because current federal policies enable activities that jeopardize patient safety ...

Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...

Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.

Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation ...